As$_2$O$_3$ 24 hours after exposing the cells to GM-CSF. In 5/8 cases the addition of GM-CSF made the cells more sensitive to the apoptotic effects of As$_2$O$_3$, particularly at concentrations as low as those known to be effective in vivo. Representative experiments are shown in Figure 1.

Two interesting observations can be drawn from our data. The initial levels of apoptosis in our experiments are strikingly similar to those observed in vivo (14% vs 10-15% in ref. #2). Moreover, a relevant proportion of cells from advanced MDS cases seem to respond in vitro to the anti-apoptotic effect of HGF. The role played by the process of cell death in the pathogenesis of MDS is still a matter of debate.4 We show here that a combination of a pro-apoptotic agent with a differentiative stimulus seems to be able to overcome the relative resistance to apoptosis documented in advanced MDS cases.

Amedea Donelli, Caterina Chiodino, Tindara Panissidi, Roberto Roncaglia, Giuseppe Torelli
Division of Hematology and Immunohematology Center, University of Modena, Italy

Key words
Arsenic trioxide, myelodysplastic syndromes.

Correspondence
Amedea Donelli, M.D., Dipartimento di Scienze Mediche Oncologiche e Radiologiche, Sezione di Medicina Interna, O ncol o gia ed Ematologia, Polidimico, via del Pozzo 71, 41100 Modena, Italy. Phone: international +059-424538 Fax: international +059-424549 E-mail: donelli.amedea@unimo.it

References

Table 1.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number of cases</th>
<th>Response to As$_2$O$_3$</th>
<th>Response to +GM-CSF</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAEB-t</td>
<td>3</td>
<td>2/3</td>
<td>ND</td>
</tr>
<tr>
<td>AML-M0</td>
<td>8</td>
<td>5/8</td>
<td>4/8</td>
</tr>
<tr>
<td>AML-M3</td>
<td>1</td>
<td>1/1</td>
<td>ND</td>
</tr>
<tr>
<td>CMML</td>
<td>1</td>
<td>0/1</td>
<td>0/1</td>
</tr>
</tbody>
</table>

Epoch-cyclosporin A induces high response rates in relapsed lymphomas

We describe the results concerning tolerance, response and survival of a program of rescue therapy for primary refractory and relapsed lymphoma combining cyclophosphamide and prednisone with a 96-hour infusion of etoposide, vincristine, and doxorubicin (EPOCH) with cyclosporin A (CsA).

Sir,

The prognosis of patients with refractory or relapsed lymphoma is very poor in spite of aggressive salvage treatments.1 Multiple molecular mechanisms involved in drug resistance have been elucidated.2 It is possible to circumvent some of them by using specific modulators.3-5 Cyclosporin A can effectively modulate multidrug resistance mediated by P-glycoprotein6 and other mechanisms.7 Otherwise, the administration of chemotherapeutic agents at lower continuous infusion can circumvent the resistance of patients treated with the same drugs administered in bolus.7

In August 1994, we began a program of rescue therapy combining EPOCH infusional chemotherapy with CsA. An intravenous (i.v.) loading dose of CsA 5 mg/kg was given over 2 hours on day 1, followed by 16 mg/kg/d as i.v.-continuous infusion on days 1 to 4. Simultaneously with the CsA continuous infusion of etoposide, vincristine, and doxorubicin were all administered on days 1 though 4. Finally, cyclophosphamide (i.v. bolus on day 6) and prednisone (orally on days 1 through 6) were given. Treatments were repeated every 4 weeks. When possible, patients achieving a response with CsA+EPOCH chemotherapy were consolidated either with high dose chemotherapy and/or radiotherapy.

The characteristics of the 13 patients treated in this way are shown in Table 1.

A total of 51 cycles of CsA+EPOCH were administered. The median number of treatment cycles per patient was two, the range 1-15. Five patients (38%) experienced grade IV leukopenia. Infectious episodes occurred in three patients, and two patients died from these. Other mild toxic events, such as grade II mucositis, fluid retention, hyperbilirubinaemia, pain, and central nervous system toxicity were frequently observed. Dose adjustments were required in 6 patients (46%).

The CsA steady-state concentrations showed a high interpatient variability (median 2,117 ng/mL, range 902-2,906). As CsA delays the clearance of some chemotherapeutic agents resulting in enhanced serum drug levels,8,9 a forty-percent dose reduction with chemotherapy were consolidated either with high dose chemotherapy and/or radiotherapy.

The characteristics of 13 patients treated in this way are shown in Table 1.
primary chemotherapy regimen. The remission rate in patients with a relapse from a complete remission was six out of seven (86%; 95% C.I.: 42.1 to 99.6%). Of interest, five of them had previously received high dose chemotherapy treatment as they had had high risk lymphomas at the time of diagnosis. Actuarial survival was 18%; median survival was 7 months (95% C.I.: 0.5 to 13) and event-free survival was 8%. Patients with primary refractory lymphoma had significantly worse overall survival than patients in relapse (median survival 2.3 vs 11.3 months; p=0.01).

In conclusion, this novel approach combines two different strategies to overcome multidrug resistance. In this pilot study, CsA+EPOCH obtained high response rates in patients with heavily pretreated relapsed lymphomas. However, we found no responses in patients with primary refractory lymphoma, suggesting that the resistance found in these tumors involves different resistance mechanisms. A better understanding of these mechanisms is necessary to design treatments which will be able to overcome multidrug resistance and to improve the survival in patients with refractory lymphoma.

Jose M. Lopez-Picazo, Ramon Gonzalez Manzano, Jose M. Ordoñez Tres, Marta Moreno Jimenez, Javier Perez Calvo, Antonio Brugarolas Departamento de Oncologia, Clinica Universitaria, Universidad de Navarra, Pamplona, Spain

Key words
Lymphoma, Cyclosporin A, relapse, resistance

Correspondence
Jose M. Lopez-Picazo, M.D., Departamento de Oncología, Clinica Universitaria, Av. Pio XII 36, Pamplona 31008 Spain. Phone: international+34-948-255400 - Fax: international+34-948-255500 - Email:jlpicazo@unav.es

References

Subacute spinal cord infarction due to zygomycotic thrombosis in a patient with myelodysplastic syndrome

A 58-year old man with myelodysplastic syndrome developed subacute-onset myelopathy, which did not respond to local irradiation. He finally died of pneumonia. The post-mortem examination revealed disseminated zygomycosis in the lung and the spinal vasculature, causing transverse spinal infarction. Disseminated zygomycosis can be responsible for myelopathy in patients with a hematologic malignancy.

Sir,

Myelopathy is rare complication in patients with a hematologic malignancy. Leukemic infiltration, infection, hemorrhages and cytotoxic agents can be responsible for this complication. We recently cared for a patient who developed myelopathy caused by...